Lv2
106 积分 2021-04-20 加入
Deep-learning-based HER2 status assessment from multimodal breast cancer data predicts neoadjuvant therapy response
13小时前
已完结
Assessment of the HER2DX Assay in Patients With ERBB2-Positive Breast Cancer Treated With Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab
23天前
已完结
Assessment of a Genomic Assay in Patients With ERBB2-Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy With or Without Pertuzumab
23天前
已完结
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
4个月前
已完结
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial
4个月前
已完结
Silent mutations make noise
5个月前
已完结
乳腺癌HER2检测指南（2024版）
7个月前
已完结
人表皮生长因子受体 2 低表达乳腺癌 临床诊疗共识 (2022 版)
1年前
已完结
Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial
1年前
已完结
Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)
1年前
已完结
皖公网安备34019202002308
